We recently published a list of Why These 10 Stocks Soared Today. In this article, we are going to take a look at where Teva Pharmaceutical Industries Limited (NYSE:TEVA) stands against other Wednesday’s best-performing stocks.
The stock market rebounded on Wednesday, with all major indices ending in the green as investors cheered the Federal Reserve’s decision to keep interest rates unchanged.
On Wednesday afternoon, the Fed kept rates steady at a range of 4.25 percent to 4.5 percent, saying that it was not in a hurry to cut rates and could still “wait and see” the impact of President Donald Trump’s tariff policies.
The Dow Jones rallied by 0.70 percent, the S&P 500 increased by 0.43 percent, and the Nasdaq grew by 0.27 percent.
Beyond the major indices, 10 firms stood out with strong gains, thanks to a flurry of fresh developments, including new partnerships, optimistic outlooks, and impressive earnings performance. In this article, we name Wednesday’s 10 best-performing stocks and detail the reasons behind their gains.
To come up with the list, we considered only the stocks with a $2-billion market capitalization and $5-million trading volume.
A close-up shot of various types of medicines on a table, illustrating the specialty and generic products offered by the pharmaceutical company.
Teva Pharmaceutical Industries Limited (NYSE:TEVA)
Teva Pharmaceutical grew its share prices by 9.18 percent on Wednesday to end at $17.60 apiece as investors cheered the company’s 9th consecutive quarter of impressive revenue performance.
In its earnings release, Teva Pharmaceutical Industries Limited said it achieved a 2-percent increase in revenues in the first three months of the year at $3.89 billion from the $3.82 billion registered in the same period last year, thanks to the higher contribution from Austedo and Uzedy’s US operations, coupled with sales from its generic products across all other segments.
The strong figures pushed the company to profitability during the quarter, having swung to an attributable net income of $214 million versus a $139 million net loss year-on-year.
Looking ahead, Teva Pharmaceutical Industries Limited posted a generally optimistic outlook for its business, saying that US tariffs are expected to have an immaterial impact.
For the full year 2025, the company expects revenues to settle anywhere between $16.8 billion and $17.2 billion.
READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires.
This article is originally published at Insider Monkey.